BR112015014855A2 - compostos radiossensibilizadores para uso em combinação com radiação - Google Patents

compostos radiossensibilizadores para uso em combinação com radiação

Info

Publication number
BR112015014855A2
BR112015014855A2 BR112015014855A BR112015014855A BR112015014855A2 BR 112015014855 A2 BR112015014855 A2 BR 112015014855A2 BR 112015014855 A BR112015014855 A BR 112015014855A BR 112015014855 A BR112015014855 A BR 112015014855A BR 112015014855 A2 BR112015014855 A2 BR 112015014855A2
Authority
BR
Brazil
Prior art keywords
combination
compounds
radiosensitizing
radiosensitizing compounds
radiation
Prior art date
Application number
BR112015014855A
Other languages
English (en)
Inventor
Lu Qing-Bin
Original Assignee
Qing Bin Lu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qing Bin Lu filed Critical Qing Bin Lu
Publication of BR112015014855A2 publication Critical patent/BR112015014855A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
    • C07C211/52—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Abstract

resumo da patente de invenã§ã£o para: “compostos radiossensibilizadores para uso em combinaã‡ãƒo com radiaã‡ãƒo”. sã£o aqui descritos compostos radiossensibilizadores ãºteis em combinaã§ã£o com a radioterapia, por exemplo, uma terapia de combinaã§ã£o sinã©rgica para o tratamento de cã¢ncer e outras doenã§as. os compostos radiossensibilizadores tãªm a fã³rmula geral i: (i) em que a representa um nãºcleo aromã¡tico; pelo menos um de ra e rb ã© um promotor de transferãªncia de elã©trons como aqui definido, por exemplo, nh2; e pelo menos um de rc representa um grupo de saã­da tal como aqui definido, por exemplo, halogãªnio; e o resto da molã©cula ã© como aqui definido. as composiã§ãµes farmacãªuticas, mã©todos, utilizaã§ãµes, kits e embalagens comerciais que compreendem os compostos radiossensibilizadores sã£o tambã©m descritos.
BR112015014855A 2012-12-20 2013-12-20 compostos radiossensibilizadores para uso em combinação com radiação BR112015014855A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261797983P 2012-12-20 2012-12-20
PCT/CA2013/051005 WO2014094178A1 (en) 2012-12-20 2013-12-20 Radiosensitizer compounds for use in combination with radiation

Publications (1)

Publication Number Publication Date
BR112015014855A2 true BR112015014855A2 (pt) 2017-07-11

Family

ID=50977492

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015014855A BR112015014855A2 (pt) 2012-12-20 2013-12-20 compostos radiossensibilizadores para uso em combinação com radiação

Country Status (10)

Country Link
US (1) US9655965B2 (pt)
EP (1) EP2935215B1 (pt)
JP (1) JP6321673B2 (pt)
KR (1) KR102278760B1 (pt)
CN (1) CN105164107B (pt)
AU (1) AU2013362757B2 (pt)
BR (1) BR112015014855A2 (pt)
CA (1) CA2895526C (pt)
MX (1) MX2015008010A (pt)
WO (1) WO2014094178A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102307387B1 (ko) 2013-10-08 2021-09-30 큉-빈 루 표적화된 화학요법에 사용하기 위한 비­백금­기반 항암 화합물
CN107438437B (zh) * 2015-04-02 2021-01-01 普罗克斯马根有限责任公司 用于癌症的治疗
CN106045932B (zh) * 2016-06-06 2018-05-15 浙江省肿瘤医院 一种具有放射增敏作用的化合物及其应用
WO2021224186A1 (en) * 2020-05-04 2021-11-11 Institut Curie New pyridine derivatives as radiosensitizers
CN114478524A (zh) * 2022-03-15 2022-05-13 江苏省肿瘤医院 1,8-萘啶类化合物及其应用
CN114560799A (zh) * 2022-03-15 2022-05-31 江苏省肿瘤医院 腈基取代苯基类化合物及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5011451B1 (pt) * 1969-05-05 1975-05-01
CH559729A5 (pt) * 1970-10-23 1975-03-14 Hoechst Ag
US3822261A (en) * 1972-10-30 1974-07-02 Dow Chemical Co 5,6-dihalo-2-fluoroalkyl-1h-imidazo(4,5-b)pyrazines
GR72941B (pt) * 1978-10-20 1984-01-16 Lilly Co Eli
US4210647A (en) * 1979-06-18 1980-07-01 Eli Lilly And Company Antiviral combinations
JPS597175A (ja) * 1982-07-01 1984-01-14 メルク・エンド・カムパニ−・インコ−ポレ−テツド 放射線治療用添加剤として有用な、クロロニトロアミノピラジン及びアルキルアミノピラジンのアミノとアミド誘導体
GB8722488D0 (en) * 1987-09-24 1987-10-28 Fujisawa Pharmaceutical Co Imidazopyridine compound
CA2138026C (en) * 1992-06-22 2003-09-09 Eckard Weber Novel 1,4-dihydroquinoxaline-2,3-diones and uses therefor as glycine receptor antagonists
CA2180122A1 (en) * 1994-01-03 1995-07-13 Sui Xiong Cai 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the usethereof as antagonists for the glycine/nmda receptor
US5753687A (en) * 1995-06-19 1998-05-19 Ontogen Corporation Modulators of proteins with phosphotryrosine recognition units
CA2397665A1 (en) * 2000-01-24 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
US6538010B1 (en) * 2000-11-08 2003-03-25 Research Triangle Institute Compounds and methods for promoting smoking cessation
GB0428082D0 (en) * 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
KR101135789B1 (ko) * 2005-04-01 2012-04-16 다이호야쿠힌고교 가부시키가이샤 피리딘 유도체를 유효성분으로 하는 방사선 치료 증강제
CN101155782B (zh) * 2005-04-01 2011-05-04 大鹏药品工业株式会社 以吡啶衍生物为有效成分的放射线治疗增强剂
US20100222345A1 (en) * 2006-08-09 2010-09-02 Caroline Jean Diaz Novel compounds as antagonists or inverse agonists for opioid receptors
WO2008042282A2 (en) * 2006-09-28 2008-04-10 Exelixis, Inc. Imidazole-4, 5-dicarboxamide derivatives as jak-2 modulators
CN101611007A (zh) * 2006-12-20 2009-12-23 先灵公司 新颖的jnk抑制剂
CN102264721B (zh) * 2008-11-10 2015-12-09 沃泰克斯药物股份有限公司 用作atr激酶抑制剂的化合物
WO2011026219A1 (en) 2009-09-01 2011-03-10 Lu qing-bin Combination therapy for cancer comprising a platinum -based antineoplastic agent and a biocompatible electron donor
WO2011143419A1 (en) * 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Pyrazines useful as inhibitors of atr kinase
GB201017345D0 (en) * 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists

Also Published As

Publication number Publication date
US20150343059A1 (en) 2015-12-03
CN105164107A (zh) 2015-12-16
CA2895526A1 (en) 2014-06-26
EP2935215A4 (en) 2016-10-26
CN105164107B (zh) 2017-12-05
KR102278760B1 (ko) 2021-07-20
EP2935215A1 (en) 2015-10-28
JP2016504325A (ja) 2016-02-12
EP2935215B1 (en) 2019-11-13
US9655965B2 (en) 2017-05-23
MX2015008010A (es) 2016-04-26
AU2013362757A1 (en) 2015-07-30
KR20150120953A (ko) 2015-10-28
AU2013362757B2 (en) 2018-06-14
WO2014094178A1 (en) 2014-06-26
CA2895526C (en) 2021-08-24
JP6321673B2 (ja) 2018-05-09

Similar Documents

Publication Publication Date Title
BR112015014855A2 (pt) compostos radiossensibilizadores para uso em combinação com radiação
BR112015023060A2 (pt) entidades químicas
BR112015027951A8 (pt) arilquinazolinas, seus usos, medicamento, composição farmacêutica, e kit
UY33440A (es) ?compuestos pirimidinílicos para uso como inhibidores de atr?.
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
BR112021022897A2 (pt) Inibidor contendo derivado bicíclico, método de preparação do mesmo e uso do mesmo
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112015011148A8 (pt) composto, composição farmacêutica, e combinação
BR112015021115A2 (pt) agentes para induzir apoptose para o tratamento de câncer e doenças imunes e autoimunes
CL2012001422A1 (es) Compuestos derivados de sulfonil benzamidas sustituidas, inductores de apoptosis con selectividad por bcl-2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
BR112015011147A8 (pt) composto, composição farmacêutica, e, uso do referido composto
CR11200A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o p13k
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
BR112014024672A8 (pt) Composições farmacêuticas para terapia de combinação
CL2014001547A1 (es) Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales.
BR112015011298A2 (pt) inibidores de cotransportador 1 de glicose de sódio
CR11199A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
BR112021026498A2 (pt) Composto, uso do composto e composição farmacêutica
BR112017004741A2 (pt) compostos e composições como inibidores da raf quinase
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112015014090A2 (pt) intensificador de inibidores de zeste homólogo 2
BR112012011457A2 (pt) uso antitumoral de cabazitaxel.
BR112012018954A2 (pt) derivados de hetaril-[1,8]naftiridina
BR112015024050A2 (pt) composto, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements